| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
84,000,000 |
| Market
Cap: |
362.88(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$2 - $11.23 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : 8.9 |
| Insider 6 Months : 8.9 |
| Insider 3/6 Months : 18 |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule single-agent and combination therapy candidates to address diseases, such as non-alcoholic steatohepatitis (NASH) and obesity. Co.'s primary program is TERN-101, a liver-distributed, non-bile acid Farnesoid X Receptor (FXR) agonist that has demonstrated sustained liver FXR activation, as well as a favorable tolerability profile across multiple clinical trials. Co.'s another clinical stage program, TERN-201, is an inhibitor of Vascular Adhesion Protein-1. Co. is also evaluating the potential to co-administer TERN-201 in combination with a metabolically active NASH treatment.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
48,314 |
48,314 |
542,714 |
553,782 |
| Total Buy Value |
$186,596 |
$186,596 |
$5,311,163 |
$5,359,325 |
| Total People Bought |
2 |
2 |
4 |
6 |
| Total Buy Transactions |
4 |
4 |
8 |
12 |
| Total Shares Sold |
0 |
37,621 |
206,949 |
627,612 |
| Total Sell Value |
$0 |
$213,457 |
$1,880,327 |
$4,677,186 |
| Total People Sold |
0 |
3 |
5 |
6 |
| Total Sell Transactions |
0 |
6 |
16 |
19 |
| End Date |
2025-04-03 |
2024-12-31 |
2024-07-02 |
2023-07-03 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Kuriakose Emil |
Chief Medical Officer |
• – – |
2025-07-01 |
4 |
S |
$4.27 |
$3,640 |
D/D |
(853) |
52,464 |
|
- |
|
| Gengos Andrew |
Chief Financial Officer |
• – – |
2025-06-27 |
4 |
B |
$3.93 |
$39,283 |
D/D |
10,000 |
25,000 |
0.01 |
11% |
|
| Burroughs Amy L. |
Chief Executive Officer |
• • – |
2025-06-25 |
4 |
B |
$3.87 |
$90,230 |
D/D |
23,314 |
47,083 |
0.01 |
5% |
|
| Gengos Andrew |
Chief Financial Officer |
• – – |
2025-06-16 |
4 |
B |
$3.95 |
$19,733 |
D/D |
5,000 |
15,000 |
0.01 |
6% |
|
| Gengos Andrew |
Chief Financial Officer |
• – – |
2025-06-13 |
4 |
B |
$3.72 |
$37,350 |
D/D |
10,000 |
10,000 |
0.01 |
10% |
|
| Kuriakose Emil |
Chief Medical Officer |
• – – |
2025-04-01 |
4 |
S |
$2.49 |
$2,366 |
D/D |
(952) |
53,317 |
|
-66% |
|
| Strauss David Eric |
Principal Accounting Officer |
• – – |
2025-02-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
89,673 |
|
-10% |
|
| Vignola Mark J. |
Chief Financial Officer |
• – – |
2025-01-06 |
4 |
AS |
$5.80 |
$52,500 |
D/D |
(9,059) |
74,752 |
|
-50% |
|
| Quigley Jill M. |
|
– • – |
2025-01-06 |
4 |
AS |
$5.79 |
$50,758 |
D/D |
(8,760) |
0 |
|
-50% |
|
| Vignola Mark J. |
Chief Financial Officer |
• – – |
2025-01-02 |
4 |
AS |
$5.72 |
$46,524 |
D/D |
(8,129) |
83,811 |
|
-51% |
|
| Kuriakose Emil |
Chief Medical Officer |
• – – |
2025-01-02 |
4 |
S |
$5.71 |
$25,607 |
D/D |
(4,481) |
54,269 |
|
51% |
|
| Quigley Jill M. |
|
– • – |
2025-01-02 |
4 |
AS |
$5.72 |
$35,702 |
D/D |
(6,240) |
8,760 |
|
-51% |
|
| Burroughs Amy L. |
Chief Executive Officer |
• • – |
2024-12-05 |
4 |
B |
$7.15 |
$110,468 |
D/D |
15,450 |
19,099 |
0.01 |
-63% |
|
| Jung Melita Sun |
Chief Business Officer |
• – – |
2024-11-30 |
4 |
B |
$5.11 |
$11,498 |
D/D |
2,250 |
2,250 |
0.01 |
-62% |
|
| Burroughs Amy L. |
Chief Executive Officer |
• • – |
2024-11-30 |
4 |
B |
$5.11 |
$2,606 |
D/D |
510 |
19,609 |
0.01 |
-62% |
|
| Lu Hongbo |
Director |
– • – |
2024-09-12 |
4 |
B |
$10.50 |
$4,999,995 |
I/I |
476,190 |
476,190 |
2.1 |
-51% |
|
| Vignola Mark J. |
Chief Financial Officer |
• – – |
2024-09-10 |
4 |
AS |
$11.00 |
$110,000 |
D/D |
(10,000) |
91,940 |
|
-60% |
|
| Vignola Mark J. |
Chief Financial Officer |
• – – |
2024-09-10 |
4 |
OE |
$5.36 |
$53,600 |
D/D |
10,000 |
101,940 |
|
- |
|
| Quigley Jill M. |
|
– • – |
2024-09-09 |
4 |
AS |
$10.00 |
$172,350 |
D/D |
(17,235) |
15,000 |
|
-51% |
|
| Quigley Jill M. |
|
– • – |
2024-09-09 |
4 |
OE |
$1.82 |
$31,368 |
D/D |
17,235 |
32,235 |
|
- |
|
| Quigley Jill M. |
|
– • – |
2024-08-02 |
4 |
AS |
$7.50 |
$66,432 |
D/D |
(8,857) |
15,000 |
|
-10% |
|
| Quigley Jill M. |
|
– • – |
2024-08-01 |
4 |
AS |
$7.68 |
$47,148 |
D/D |
(6,143) |
23,857 |
|
-11% |
|
| Quigley Jill M. |
|
– • – |
2024-07-16 |
4 |
AS |
$10.00 |
$4,000 |
D/D |
(400) |
30,000 |
|
-41% |
|
| Quigley Jill M. |
|
– • – |
2024-07-16 |
4 |
OE |
$1.82 |
$728 |
D/D |
400 |
30,400 |
|
- |
|
| Gordon Carl L |
Director |
– • • |
2024-07-16 |
4 |
S |
$10.00 |
$51,880 |
I/I |
(5,188) |
755,635 |
|
41% |
|
76 Records found
|
|
Page 1 of 4 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.06 (1.41%) 
